<DOC>
	<DOCNO>NCT00389584</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Irinotecan may make tumor cell sensitive radiation therapy . Giving irinotecan together whole-brain radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose irinotecan give together whole-brain radiation therapy see well work treat patient brain metastasis solid tumor . ( The study side effect best dose end 4/15/05 )</brief_summary>
	<brief_title>Irinotecan Whole-Brain Radiation Therapy Treating Patients With Brain Metastases From Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose irinotecan hydrochloride administer concurrently whole-brain radiotherapy patient brain metastasis solid tumor . ( Phase I ) ( Phase I close accrual 4/15/05 ) - Determine toxicity regimen patient . ( Phase I ) ( Phase I close accrual 4/15/05 ) - Determine overall survival patient treat regimen . ( Phase II ) Secondary - Assess neurocognitive function patient Mini-Mental Status Examination . ( Phase II ) OUTLINE : This phase I , dose-escalation study irinotecan hydrochloride ( phase I close accrual 4/15/05 ) follow phase II study . Patients enrol phase II stratify accord cognitive dysfunction ( yes v ) . - Phase I ( close accrual 4/15/05 ) : Patients undergo whole-brain radiotherapy ( WBRT ) daily , 5 day week , 3 week ( 15 fraction ) . Patients also receive irinotecan hydrochloride IV 90 minute day 1 , 8 , 15 . Cohorts 3-6 patient receive escalate dos irinotecan hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II ( patient enrol 4/15/05 ) : Patients receive irinotecan hydrochloride MTD undergo concurrent WBRT phase I . Patients complete Mini-Mental Status Examination assess neurocognitive function baseline , last day radiotherapy , periodically completion study therapy . After completion study therapy , patient follow monthly 3 month , 6 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 51 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis brain metastasis histologically confirm solid tumor , meet follow criterion : Must histologic proof original malignancy No germ cell tumor metastasis Biopsyproven brain metastasis preferred clinical history radiographic finding equivocal At least 1 unidimensionally measurable lesion ≥ 50 mm head contrast CT scan and/or brain MRI Patients enrol phase II portion study must meet follow Radiation Therapy Oncology Group Recursive Partitioning Analysis stag criterion brain metastasis : Class II classification Zubrod performance status 01 AND follow : Age &gt; 65 year Extracranial metastasis Uncontrolled primary malignancy PATIENT CHARACTERISTICS : Zubrod performance status 01 Life expectancy ≥ 3 month Able participate MiniMental Status Examination WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL AST ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Hemoglobin ≥ 9.0 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent medical disease , investigator 's opinion , would preclude study participation PRIOR CONCURRENT THERAPY : More 21 day since prior chemotherapy No prior wholebrain radiotherapy No prior DNA topoisomerase I drug ( e.g. , irinotecan hydrochloride , topotecan hydrochloride ) At least 4 day since prior concurrent know CYP3A4 inducer , include follow : Phenytoin Carbamazepine Phenobarbital Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>poor performance status</keyword>
	<keyword>long-term effect secondary cancer therapy adult</keyword>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>adult tumor metastatic brain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>